| A22 | STAT modulation as strategy to improve NK cell cytotoxicity against HIV and cancer | On-demand oral abstract session | Immunotherapy: Immune-Modifying Agents |
| A22 | Dual IL-10 and PD-1 blockade in SIVmac239 infected macaques promotes sustained virologic control in absence of ART | Oral abstract session with live Q&A | Immunotherapy: Immune-Modifying Agents |
| A23 | RNA-directed gene therapy protects CD4+ T cells during HIV challenge and delays virus rebound post-ART in humanized mice | On-demand oral abstract session | Gene therapy |
| A23 | Novel vector systems towards a cure for HIV/AIDS | E-poster | Gene therapy |
| A23 | Using the CRISPR-Cas9 system to cure cells from HIV and at the same time prevent super-infection by new HIV strains | E-poster | Gene therapy |
| A23 | Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a and b systems | E-poster | Gene therapy |
| A23 | A novel design algorithm to predict the silencing activity of siRNA | E-poster | Gene therapy |
| A25 | Early antiretroviral therapy favors post-treatment SIV control, which is associated with enhanced CD8+ T-cell antiviral activity against rebounding virus ' the pVISCONTI study | On-demand oral abstract session | HIV-1 controllers (including post-treatment controllers) and long-term non-progressors |
| A25 | Increased platelet activation and inflammation markers associated to cardiovascular risk in HIV controllers | E-poster | HIV-1 controllers (including post-treatment controllers) and long-term non-progressors |
| A28 | Vaginal proteome signatures of unprotected sex | E-poster | Mechanism of transmission (mucosal, vertical, blood-borne) |